Spherical Nucleic Acids for Targeted T-Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid therapies face challenges in delivering therapeutic nucleic acids into cells, as unmodified linear nucleic acids do not enter cells significantly without transfection agents, and existing methods lack targeted delivery and specificity for cancer treatment.
Innovation Solution
Spherical nucleic acids (SNAs) are used to load cells ex vivo with immunostimulatory oligonucleotides and antigens, creating T-cell chaperones that can target tumor sites and lymph systems, avoiding non-target organ distribution and enabling controlled immunotherapeutic actions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If unmodified linear nucleic acids are used for delivery, then the therapeutic nucleic acids cannot enter cells significantly, but using transfection agents increases complexity and potential toxicity
Solution Approach 1:
The patent transforms linear nucleic acids into spherical nucleic acid (SNA) nanoconjugates with a three-dimensional architecture. This structural parameter change enables the nucleic acids to be actively transported across cell membranes by engaging Class A scavenger receptors, achieving reliable cellular delivery without requiring transfection agents.
Solution Approach 2:
The patent creates composite SNA structures consisting of a nanoparticle core with densely functionalized nucleic acid shells. This composite architecture combines the advantages of nanoparticle delivery systems with the therapeutic functionality of nucleic acids, enabling efficient cellular uptake while maintaining therapeutic activity.
2Reliability
If SNAs are injected directly into patients, then distribution occurs throughout the body, but this causes off-target side effects and reduces treatment specificity
Solution Approach 1:
The patent applies SNAs to treat a subset of cells ex vivo before reinfusion into the patient. This preliminary action allows for controlled environment interaction between SNAs and cells, enabling targeted modification of specific cell populations (such as T-cells) before their reintroduction, thereby achieving treatment specificity and avoiding off-target side effects.
3Productivity
If conventional nucleic acid delivery methods are used, then transfection efficiency is low, but SNAs require complex nanoconjugate synthesis
Solution Approach 1:
The patent employs spherical nucleic acid nanoconjugates where nucleic acids are organized in a three-dimensional spherical architecture around a nanoparticle core. This spheroidal structure provides privileged access at both cellular and tissue levels, with the curved surface enabling active transport across cell membranes and efficient cellular internalization, achieving high transfection efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
SNAs facilitate superior activation and targeting of T-cells to tumor sites, reducing off-target side effects and enhancing cancer treatment efficacy by promoting immune responses and direct tumor cell attack.
Implementation Method 1
SNAs are actively transported across cell membranes by engaging Class A scavenger receptors
Implementation Method 2
the polyvalent, densely functionalized nucleic acid shell that defines an SNA can act as a high affinity binder for different classes of ligands, including certain receptor proteins and complementary nucleic acid sequences
Data Source
AI summary
The disclosure is related to compositions comprising a cell and a spherical nucleic acid (SNA) comprising a nanoparticle, an oligonucleotide on the surface of the nanoparticle, and an antigen; and to methods for production of such compositions and their applications, including but not limited to adoptive cell therapy.